Farbod Hatami

Farbod Hatami

Auto-generated profile, based on publicly available information

Farbod Hatami

Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2021 in Cancer Investigation
Verified
Journal Article
Closed access
MAMona Ariamanesh
Mona Ariamanesh
PPPejman Porouhan
Pejman Porouhan
BPBabak PeyroShabany
Babak PeyroShabany
DFDanial Fazilat-Panah
Danial Fazilat-Panah
MDMansoureh Dehghani
Mansoureh Dehghani
SJSeyed Alireza Javadinia
Seyed Alireza Javadinia
To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 an...

11 November 2021 in Cancer Investigation
Verified
Journal Article
Closed access
SJSeyed Alireza Javadinia
Seyed Alireza Javadinia
MAMona Ariamanesh
Mona Ariamanesh
MNMaryam Nabavifard
Maryam Nabavifard
PPPejman Porouhan
Pejman Porouhan
BPBabak PeyroShabany
Babak PeyroShabany
MDMansoureh Dehghani
Mansoureh Dehghani
Patients with cancer are at significantly greater risk of COVID-19 and its complications than the general population. Since IgG antibodies remain detectable well after infection with the SARS-CoV-2 virus, seroprevalence can be used to estimate the proportion of the cancer population previously infected and potentially immune to SARS-CoV-2. The current study is a multi-center, prospective observational study to assess the seroprevalence of SARS-CoV-2 IgG antibody in a cancer population referred for vaccination between April and June 2021. Of a total of 270 adult patients with cancer accrued, 16% reported a history of COVID-19 more than four weeks previously confirmed by PCR. At the same time, serologic positivity for SARSCoV2 IgG was found in 29% of patients prior to vaccination including nearly 20% of patients without a history of confirmed COVID-19. Seropositivity was significantly greater in females consistent with higher rates in patients with breast cancer and gynecologic cancers. A seroconversion rate of 79.5% was observed in cancer patients with a history of PCR confirmed COVID-19, less than observed in the general population. In multivariable analysis, gender and prior history of COVID-19 were both independently associated with seropositivity prior to vaccination. Follow-up is continuing of this cohort of patients with cancer following vaccination to assess antibody and clinical outcomes.

28 September 2020 in Journal of Cardiac Surgery
Verified
Journal Article
Closed access
PDF file
FHFarbod Hatami
Farbod Hatami
NVNiloufar Valizadeh
Niloufar Valizadeh
FSForod Salehi
Forod Salehi
MMMahmood Hosseinzadeh Maleki
Mahmood Hosseinzadeh Maleki

6 December 2021 in Journal of Cardiovascular and Thoracic Research
Verified
Journal Article
Open access
PDF file
FJFarzad Jalali
Farzad Jalali
FHFarbod Hatami
Farbod Hatami
MSMehrdad Saravi
Mehrdad Saravi
IJIraj Jafaripour
Iraj Jafaripour
MHMohammad Taghi Hedayati
Mohammad Taghi Hedayati
NZnaghmeh ziaei
naghmeh ziaei
Introduction: To address cardiovascular (CV) complications and their relationship to clinical outcomes in hospitalized patients with COVID-19. Methods: A total of 196 hospitalized patients with COVID-19 were enrolled in this retrospective single-center cohort study from September 10, 2020, to December 10, 2020, with a median age of 65 years (IQR, 52-77). Follow-up continued for 3 months after hospital discharge. Results: CV complication was observed in 54 (27.6%) patients, with arrhythmia being the most prevalent (14.8%) followed by myocarditis, acute coronary syndromes, ST-elevation myocardial infarction, cerebrovascular accident, and deep vein thrombosis in 15 (7.7%), 12 (6.1%), 10(5.1%), 8 (4.1%), and 4 (2%) patients, respectively. The proportion of patients with elevated high-sensitivity troponin I, N-terminal pro-B-type natriuretic peptide, left ventricular diastolic dysfunction, and heart failure with preserved ejection fraction was greater in the CV complication group. Severe forms of COVID-19 comprised nearly two-thirds (64.3%) of our study population and constituted a significantly higher share of the CV complication group members (75.9%vs 59.9%; P=0.036). Intensive care unit admission (64.8% vs 44.4%; P=0.011) and stay (5.5days vs 0 day; P=0.032) were notably higher in patients with CV complications. Among 196patients, 50 died during hospitalization and 10 died after discharge, yielding all-cause mortality of 30.8%. However, there were no between-group differences concerning mortality. Age, heart failure, cancer/autoimmune disease, disease severity, interferon beta-1a, and arrhythmia were the independent predictors of all-cause mortality during and after hospitalization. Conclusion: CV complications occurred widely among COVID-19 patients. Moreover,arrhythmia, as the most common complication, was associated with increased mortality.

7 February 2022 in The Journal of Tehran University Heart Center
Verified
Journal Article
Open access
AEAlireza Ehsanbakhsh
Alireza Ehsanbakhsh
FHFarbod Hatami
Farbod Hatami
NVNiloufar Valizadeh
Niloufar Valizadeh
NKNasrin Khorashadizadeh
Nasrin Khorashadizadeh
FNFarshad Norouzirad
Farshad Norouzirad
Background: Computed tomography pulmonary angiography (CTPA) as the gold-standard examination in the detection of pulmonary embolism (PE) is contraindicated or unavailable in certain cases. The current study aimed to assess the accuracy of unenhanced CT in the diagnosis of PE. Methods: This cohort study was conducted between October 2020 and March 2021 in Birjand, Iran, on 195 participants with clinical suspicion of PE examined with multidetector computed tomography (MDCT) scanning and CTPA. The patients were categorized into 2 groups based on the diagnosis PE in CTPA results. Imaging variables in unenhanced CT scans, including hyper/hypodense intraluminal signs, pulmonary trunk enlargements, peripheral wedge-shaped opacities, and pleural effusions, were independently reviewed by 2 radiologists and then compared between the groups. Results: There were 82 men (42.1%) and 113 women (57.9%) at a mean age ± standard deviation of 56.00±0.24 years. Based on CTPA results, PE was diagnosed in 24.1% of the study population (47/195). However, only 20 cases (42.5%) were detected by MDCT: 17 cases (85.0%) with central PE and 3 cases (15.0%) with peripheral PE. Concerning the intraluminal clot density, 12 patients (60.0%) had hyperdense signs, 3 (15.0%) had hypodense signs, and 5 (25.0%) had mixed hyper/hypodense signs. There was a significant difference between central PE and peripheral PE detected by MDCT. Intraluminal signs had the highest specificity and sensitivity (98.6% and 42.5%, area under the curve =0.734). Conclusion: Unenhanced MDCT has a remarkable performance in detecting PE, specifically central clots, and can, therefore, be considered an alternative modality when CTPA is not available or indicated.

4 March 2022 in Radiology Case Reports
Verified
Journal Article
Open access
RVRahim Vakili
Rahim Vakili
MMMoein Mobini
Moein Mobini
FHFarbod Hatami
Farbod Hatami
SVSaba Vakili
Saba Vakili
NVNiloufar Valizadeh
Niloufar Valizadeh
Meire-Gorlin syndrome (MGS) is a rare autosomal recessive disorder characterized by a triad of short stature, microtia, and absent or hypoplastic patella. We report a 5-year-old male affected with the subtype MGS1, secondary to c.c2292t mutation of ORC1 gene. Our patient's features included a triangular face, micrognathia, and delayed motor development. To the edge of our knowledge, this is the first diagnosed Iranian MGS patient and sixth case in the middle east. MGS1 subtype has never shown improvement to growth hormone therapy, therefore underlying molecular defect was suggested to be responsible for patients’ short stature rather than growth hormone deficiency. However, our patients’ growth velocity was improved by growth hormone. We recommend more studies to specify the role of ORC1 gene in this syndrome. In addition, this case report describes the prenatal investigations and sonographic examinations of MGS1 for the first time.